Delivering Breakthrough Vaccines

IVT's goal is to generate sustainable, long-term revenues by developing and commercializing VacciMax® based vaccines through early clinical development, multiple partnerships and licensing agreements with major vaccine companies.

	LATEST NEWS

	Warwick Kimmins Science Scholarship Awarded
	ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
	ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax™ with novel MRI Imaging
	Swine Flu Situation Highlights Crucial Need for Sustained Dialogue on Vaccines in Canada
	Search on for better anthrax protection

COMPANY PROFILE

ImmunoVaccine Technologies Inc. (IVT) is a pre-clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. IVT is commercializing breakthrough vaccines developed through the combination of the VacciMax® platform, a vaccine delivery and enhancement system and a large selection of validated vaccine antigens. The combination of the right antigens and strong novel delivery will give IVT’s pipeline a distinct competitive advantage and will position IVT as a key player in development of premium vaccine products.

The VacciMax® platform is able to stimulate an earlier, more powerful, long lasting antibody and cellular immune response. IVT is also able to reduce the number of doses required for protection against infectious diseases like influenza. IVT has completed the scale-up and manufacturing method development for the VacciMax® platform. The company is planning to begin a Phase 1 clinical trial for a therapeutic cancer vaccine in 2009.

For more information, please go to our Document Library www.deliveringbreakthroughs.com